Updated Guidelines on Infertility and Hormones: A Focus on Women's Health
Key Findings on Ovarian Insufficiency
In a recent journal publication by the Centre for Research Excellence in Women's Health in Reproductive Life, updated recommendations on the diagnosis and management of premature ovarian insufficiency (POI) are outlined. Conducted by Nick Panay, M.D., and his team from Queen Charlotte's Hospital, these guidelines emphasize an evidence-based approach that incorporates feedback from women experiencing POI.
What’s New in the Guidelines?
- The prevalence of POI is acknowledged to be approximately 3.5 percent, a figure previously underestimated.
- 145 recommendations have been introduced, including expanded clinical questions around anti-Müllerian hormone (AMH) and its role in diagnosing POI.
- Follicle-stimulating hormone (FSH) >25 IU is now deemed sufficient for a POI diagnosis.
Additional guidance includes the necessity for genetic testing, updated estrogen dosing regimens, and insights into testosterone therapy. This comprehensive revision aims to enhance understanding and treatment options available for women.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.